10:30am Natco Pharma in News: Natco Pharma launched the first generic version of
sofosbuvir in Nepal.
Sofosbuvir is a medicine used for
chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi. Natco priced its generic medicine at an MRP of Rs
19,900 for a bottle of 28 tablets in Nepal.
"Natco markets generic
sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India
soon, subject to approval from the Drugs Controller General of India
(DCGI)," said the company in its filing to the exchange.
Natco had recently signed a
non-exclusive licensing agreement with Gilead Sciences, to manufacture and
sell generic versions of its chronic hepatitis C medicines in 91 developing
countries.
10:15am FII View: Ridham Desai, Morgan Stanley says, "We think the
market will slowly move away from quality in favor of growth, operating
leverage and eventually, financial leverage."
"Our stock-picking approach
remains to buy cyclicals & stocks with growth at a reasonable price
(GARP) orientation, although, as usual, we avoid beta," he adds.
10:00am Market Check
Profit booking is dragging
benchmark indices as the Sensex is down 343.04 points or 1 percent at
29105.91. The Nifty falls 111.40 points or 1 percent at 8826.35. About 690
shares have advanced, 1240 shares declined, and 157 shares are unchanged.
Sesa Sterlite, GAIL, Axis Bank,
Tata Power and ICICI Bank are major losers while Dr Reddy's Labs, HUL, Coal
India, Cipla and Reliance are top gainers in the Sensex.
The rupee plummeted by 50 paise to
62.66 against the US dollar in early trade today as the American currency
strengthened overseas. Forex dealers said besides the dollar's gains against
other currencies overseas on an upbeat US jobs data, fresh demand from
importers for the Greenback and a weak opening in the domestic stock market
put pressure on the rupee. The domestic unit had gained 9 paise to finish at
62.16 against the American currency on Thursday on the back of dollar selling
by banks and exporters amid rise in equities. More information please visit
this site www.bigprofitbuzz.com
|
Use this space to put some text. Update this text in HTML
No comments:
Post a Comment